Cancer immunotherapy: activating innate and adaptive immunity through CD40 agonists

A Cancer Research UK phase I study evaluating safety, tolerability, and biological effects of chimeric anti-CD40 monoclonal antibody (MAb), Chi Lob 7/4.

(2017) P. W. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunostimulatory AdCD40L gene therapy combined with low-dose cyclophosphamide in metastatic melanoma patients

(2016) Angelica Loskog et al.   BRITISH JOURNAL OF CANCER

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

CSF-1R–Dependent Lethal Hepatotoxicity When Agonistic CD40 Antibody Is Given before but Not after Chemotherapy

(2016) Katelyn T. Byrne et al.   JOURNAL OF IMMUNOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

IFN  and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma

(2016) K. B. Long et al.   Cancer Discovery

CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer

(2016) Katelyn T. Byrne et al.   Cell Reports

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies

(2015) Ann L. White et al.   CANCER CELL

Abstract 2472: SEA-CD40, a sugar engineered non-fucosylated anti-CD40 antibody with improved immune activating capabilities

(2015) Shyra J. Gardai et al.   CANCER RESEARCH

Abstract CT137: Combination of agonistic CD40 monoclonal antibody CP-870,893 and anti-CTLA-4 antibody tremelimumab in patients with metastatic melanoma

(2015) David L. Bajor et al.   CANCER RESEARCH

Clinical and Biological Effects of an Agonist Anti-CD40 Antibody: A Cancer Research UK Phase I Study

(2015) P. Johnson et al.   CLINICAL CANCER RESEARCH

Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6Clow F4/80+ Extratumoral Macrophages

(2015) Gregory L. Beatty et al.   GASTROENTEROLOGY

ERRATA

(2015)   JOURNAL OF CLINICAL ONCOLOGY

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

(2015) Dirk Schadendorf et al.   JOURNAL OF CLINICAL ONCOLOGY

Human Anti-CD40 Antibody and Poly IC:LC Adjuvant Combination Induces Potent T Cell Responses in the Lung of Nonhuman Primates

(2015) Elizabeth A. Thompson et al.   JOURNAL OF IMMUNOLOGY

Induced PD-L1 Expression Mediates Acquired Resistance to Agonistic Anti-CD40 Treatment

(2015) A. Zippelius et al.   Cancer Immunology Research

Systemic Agonistic Anti-CD40 Treatment of Tumor-Bearing Mice Modulates Hepatic Myeloid-Suppressive Cells and Causes Immune-Mediated Liver Damage

(2015) José Medina-Echeverz et al.   Cancer Immunology Research

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

(2015) R. Winograd et al.   Cancer Immunology Research

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

The Human Agonistic CD40 Antibody ADC-1013 Eradicates Bladder Tumors and Generates T-cell-Dependent Tumor Immunity

(2014) S. M. Mangsbo et al.   CLINICAL CANCER RESEARCH

CD40 expression in renal cell carcinoma is associated with tumor apoptosis, CD8+ T cell frequency and patient survival

(2014) Jonathan M. Weiss et al.   HUMAN IMMUNOLOGY

Fcγ Receptor Dependency of Agonistic CD40 Antibody in Lymphoma Therapy Can Be Overcome through Antibody Multimerization

(2014) Ann L. White et al.   JOURNAL OF IMMUNOLOGY

Regulatory T Cells and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment Undergo Fas-Dependent Cell Death during IL-2/ CD40 Therapy

(2014) J. M. Weiss et al.   JOURNAL OF IMMUNOLOGY

CD40L expression permits CD8+ T cells to execute immunologic helper functions

(2013) M. Frentsch et al.   BLOOD

Phase IA/II, multicentre, open-label study of the CD40 antagonistic monoclonal antibody lucatumumab in adult patients with advanced non-Hodgkin or Hodgkin lymphoma

(2013) Michelle Fanale et al.   BRITISH JOURNAL OF HAEMATOLOGY

A Phase I Study of an Agonist CD40 Monoclonal Antibody (CP-870,893) in Combination with Gemcitabine in Patients with Advanced Pancreatic Ductal Adenocarcinoma

(2013) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma

(2013) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Aging predisposes to acute inflammatory induced pathology after tumor immunotherapy

(2013) Myriam N. Bouchlaka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

(2013) Daniel D. Von Hoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ex Vivo Assays of Dendritic Cell Activation and Cytokine Profiles as Predictors of In Vivo Effects in an Anti-Human CD40 Monoclonal Antibody ChiLob 7/4 Phase I Trial

(2013) F. Chowdhury et al.   Cancer Immunology Research

Locally Delivered CD40 Agonist Antibody Accumulates in Secondary Lymphoid Organs and Eradicates Experimental Disseminated Bladder Cancer

(2013) L. C. Sandin et al.   Cancer Immunology Research

Role of Crosslinking for Agonistic CD40 Monoclonal Antibodies as Immune Therapy of Cancer

(2013) L. P. Richman et al.   Cancer Immunology Research

Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

(2013) Robert H. Vonderheide et al.   OncoImmunology

Delineation of antigen-specific and antigen-nonspecific CD8+ memory T-cell responses after cytokine-based cancer immunotherapy

(2012) J. K. Tietze et al.   BLOOD

Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

(2012) Paolo P. Provenzano et al.   CANCER CELL

Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo

(2012) Chengwen Liu et al.   JOURNAL OF IMMUNOTHERAPY

Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia

(2012) John C. Byrd et al.   LEUKEMIA & LYMPHOMA

Local Activation of CD8 T Cells and Systemic Tumor Eradication without Toxicity via Slow Release and Local Delivery of Agonistic CD40 Antibody

(2011) M. F. Fransen et al.   CLINICAL CANCER RESEARCH

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans

(2011) G. L. Beatty et al.   SCIENCE

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

CD40 Pathway Activation Status Predicts Response to CD40 Therapy in Diffuse Large B Cell Lymphoma

(2011) B. Burington et al.   Science Translational Medicine

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies

(2010) H. M. Horton et al.   BLOOD

AdCD40L Immunogene Therapy for Bladder Carcinoma--The First Phase I/IIa Trial

(2010) P.-U. Malmstrom et al.   CLINICAL CANCER RESEARCH

CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus

(2010) Taha Elmetwali et al.   Molecular Cancer

Optimized Peptide Vaccines Eliciting Extensive CD8 T-Cell Responses with Therapeutic Antitumor Effects

(2009) H.-I. Cho et al.   CANCER RESEARCH

BCL6 cooperates with CD40 stimulation and loss of p53 function to rapidly transform primary B cells

(2009) Saritha Kusam et al.   INTERNATIONAL JOURNAL OF CANCER

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment

(2009) J. M. Weiss et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of Hedgehog Signaling Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer

(2009) K. P. Olive et al.   SCIENCE

Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity

(2009) Jennifer A. McWilliams et al.   VACCINE

Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines

(2008) C. L. Ahonen et al.   BLOOD

Macrophages and Fc-receptor interactions contribute to the antitumour activities of the anti-CD40 antibody SGN-40

(2008) E Oflazoglu et al.   BRITISH JOURNAL OF CANCER

In vivo Expansion, Persistence, and Function of Peptide Vaccine-Induced CD8 T Cells Occur Independently of CD4 T Cells

(2008) D. Assudani et al.   CANCER RESEARCH

Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

(2008) Cornelia Hömig-Hölzel et al.   JOURNAL OF EXPERIMENTAL MEDICINE